Pt-141 nasal spray

The only FDA-approved compound that reaches the brain to trigger sexual desire — rather than dilating blood vessels — has done so in exactly one population: premenopausal women with hypoactive sexual desire disorder. PT-141's nasal spray formulation delivers bremelanotide through the nasal mucosa into systemic circulation, where it crosses the blood-brain barrier and binds melanocortin receptors in neural tissue. The clinical data supporting this mechanism is stronger for women than men, which is the reverse of nearly every other sexual dysfunction treatment in existence.

A Melanocortin Receptor Agonist Derived From a Tanning Peptide

PT-141 is a synthetic cyclic heptapeptide, specifically a seven-amino-acid peptide with a ring structure created by an intramolecular lactam bridge. Its molecular weight is 1025.18 Da. The compound originated from research on Melanotan II, a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) developed in the 1980s at the University of Arizona for tanning applications. During early human trials of Melanotan II, researchers observed unexpected pro-sexual effects in male subjects — spontaneous erections and increased arousal independent of visual or tactile stimulation.

Palatin Technologies isolated this pro-sexual activity by modifying the Melanotan II structure to reduce melanocortin-1 receptor (MC1R) binding, which mediates pigmentation, while preserving activity at MC3R and MC4R. The result was bremelanotide, assigned the research designation PT-141. The compound retains the cyclic structure that provides metabolic stability, a feature absent in linear peptides that are rapidly degraded by peptidases in plasma and tissue.

PT-141's development path was unusual. After initial trials in male erectile dysfunction showed cardiovascular side effects when administered subcutaneously, Palatin reformulated the compound as a nasal spray and pivoted to female sexual dysfunction. The FDA approved Vyleesi (bremelanotide nasal spray) in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. No equivalent approval exists for men.

Central Melanocortin Receptor Activation Without Vascular Mediation

PT-141 functions as an agonist at melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R), both of which are G protein-coupled receptors (GPCRs) expressed in the central nervous system. MC4R is densely expressed in the paraventricular nucleus (PVN) of the hypothalamus, the medial preoptic area (MPOA), and other limbic structures involved in sexual behavior. MC3R is co-expressed in some of the same regions, though its specific role in sexual function is less well characterized.

When PT-141 binds MC4R, it activates the Gαs signaling pathway, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). This cAMP accumulation activates protein kinase A (PKA), which phosphorylates downstream targets including CREB (cAMP response element-binding protein), a transcription factor that regulates gene expression. In hypothalamic neurons, this cascade modulates neuronal excitability and neurotransmitter release, particularly oxytocin and dopamine, both of which are implicated in sexual arousal and desire.

The key distinction between PT-141 and phosphodiesterase-5 (PDE5) inhibitors such as sildenafil is the site of action. PDE5 inhibitors work peripherally by enhancing nitric oxide-mediated vasodilation in genital tissue, facilitating erectile function in men but not directly addressing desire or arousal pathways in the brain. PT-141 crosses the blood-brain barrier after intranasal administration and acts centrally. In animal models, lesioning the PVN abolishes PT-141's pro-sexual effects, confirming the hypothalamic origin of its activity.

In rodent studies, MC4R knockout mice do not display the pro-sexual behavioral changes seen in wild-type animals administered melanocortin agonists. This genetic loss-of-function evidence supports MC4R as the primary receptor mediating PT-141's effects. The compound also shows some activity at MC3R, but selective MC3R agonists do not replicate PT-141's sexual behavior effects, suggesting MC4R is the dominant target.

Two Phase III Trials in Women, Inconsistent Evidence in Men

The strongest human evidence for PT-141 comes from two Phase III randomized controlled trials (RCTs) in premenopausal women with HSDD. RECONNECT was a 24-week, double-blind, placebo-controlled trial enrolling 1,267 women. Subjects self-administered subcutaneous bremelanotide (1.75 mg) or placebo as needed before anticipated sexual activity, with a maximum of one dose per 24 hours and eight doses per month. The co-primary endpoints were change from baseline in the number of satisfying sexual events (SSEs) and change in sexual desire score measured by the Female Sexual Function Index-desire domain (FSFI-d).

At 24 weeks, bremelanotide-treated women reported a mean increase of 0.5 additional SSEs per month compared to placebo (p < 0.001). The FSFI-d score increased by 0.3 points more in the treatment group than placebo (p < 0.001). Both differences were statistically significant but modest in absolute magnitude. About 25% of women in the treatment group reported nausea, compared to 1% in placebo. Flushing occurred in 20% of bremelanotide users versus 1% of placebo.

A second Phase III trial, also 24 weeks in duration, replicated these findings with similar effect sizes and adverse event profiles. Pooled analysis across both trials showed consistent small-to-moderate increases in sexual desire and satisfying events, with nausea remaining the most common treatment-limiting side effect. Based on this data, the FDA approved bremelanotide subcutaneous injection in 2019. A nasal spray formulation is currently marketed, though the approval was based on subcutaneous dosing data.

The male erectile dysfunction data is weaker and more heterogeneous. Early Phase II trials using subcutaneous bremelanotide in men with mild-to-moderate ED showed improvement in erectile function compared to placebo, but subsequent trials revealed transient blood pressure increases (mean systolic increase of 10-15 mmHg) lasting 8-12 hours post-dose. Palatin halted male ED development due to cardiovascular risk concerns.

No large-scale RCTs have been published evaluating PT-141 nasal spray specifically for male sexual dysfunction. Small pilot studies (n < 50) have shown mixed results, with some reporting subjective increases in arousal but no consistent improvement in objective erectile measures compared to baseline. The compound's efficacy in men remains uncertain outside of anecdotal reports. For research purposes only, PT-141 is often used off-label in male populations despite the absence of FDA approval for this indication.

Intranasal Dosing, Rapid Onset, and a 2-3 Hour Half-Life

Published clinical trials in women used a subcutaneous dose of 1.75 mg bremelanotide, self-administered 45-60 minutes before anticipated sexual activity. The commercially available nasal spray formulation delivers bremelanotide at the same 1.75 mg dose per actuation. Intranasal administration results in rapid absorption through the highly vascularized nasal mucosa, with plasma levels detectable within 15 minutes. Peak plasma concentration (Cmax) occurs at approximately 60 minutes post-dose, slightly earlier than subcutaneous administration, which peaks around 75 minutes.

The terminal elimination half-life of bremelanotide following intranasal or subcutaneous administration is approximately 2.7 hours. Despite this short half-life, the duration of pro-sexual effects extends beyond the compound's plasma presence, suggesting that the activated signaling cascades in hypothalamic neurons persist after the peptide has been cleared. Women in clinical trials reported effects lasting 4-8 hours post-administration, well beyond the expected clearance time.

PT-141 is metabolized primarily by peptidases in plasma and tissue, yielding inactive fragments. Renal clearance accounts for a minor fraction of elimination. No hepatic cytochrome P450 enzyme involvement has been identified, which reduces the risk of drug-drug interactions mediated by CYP450 inhibitors or inducers.

Stability is a consideration for nasal spray formulations. Peptides are vulnerable to aggregation and degradation when stored in aqueous solution. The commercial product is formulated with stabilizers and requires refrigeration (2-8°C) prior to first use. After initial priming, the device can be stored at room temperature for up to 7 days. Freeze-thaw cycles degrade peptide integrity and should be avoided. Research-grade PT-141 powder is typically stored lyophilized at -20°C.

Transient blood pressure elevation is a documented effect. In clinical trials, blood pressure monitoring showed a mean systolic increase of 10 mmHg within 2 hours of dosing, returning to baseline by 12 hours. Subjects with pre-existing hypertension or cardiovascular disease were excluded from trials, so the hemodynamic response in higher-risk populations is unknown. Nausea occurred in approximately 25% of women in Phase III trials, often resolving with repeat dosing (tachyphylaxis), but leading to discontinuation in about 4% of subjects.

FAQ

Q: How does PT-141 differ from PDE5 inhibitors like Viagra?

PT-141 acts on melanocortin receptors in the brain to increase sexual desire and arousal via hypothalamic signaling, whereas PDE5 inhibitors work peripherally by enhancing blood flow to genital tissue. PT-141 crosses the blood-brain barrier; sildenafil does not. This makes PT-141 a desire-targeting agent rather than a vasodilatory agent.

Q: Why is PT-141 approved for women but not men?

The Phase III trials demonstrating efficacy and acceptable safety were conducted exclusively in premenopausal women with HSDD. Earlier male ED trials showed efficacy but also revealed transient blood pressure increases that raised cardiovascular safety concerns, leading Palatin to discontinue development for male indications. No large-scale male trials have been completed with the nasal spray formulation.

Q: Does PT-141 cause tanning or pigmentation changes?

PT-141 was specifically designed to reduce melanocortin-1 receptor (MC1R) binding compared to its parent compound Melanotan II, minimizing pigmentation effects. Clinical trial data in women did not report increased tanning or darkening of skin as an adverse event. However, residual MC1R activity may occur at higher-than-approved doses.

Q: What is the typical onset time for PT-141 effects after nasal administration?

Plasma levels become detectable within 15 minutes, and peak concentration occurs around 60 minutes post-dose. Subjectively reported effects in clinical trials began 45-90 minutes after administration, with peak effects around 2-3 hours. Individual response variability is high.

Q: Can PT-141 be used daily, or is it an on-demand treatment?

PT-141 was studied and approved as an on-demand treatment, administered before anticipated sexual activity with a maximum of one dose per 24 hours and no more than eight doses per month. Daily chronic dosing has not been evaluated in clinical trials, and the hemodynamic effects (transient blood pressure increase) make daily use inadvisable outside of controlled research settings.

---

This content is for informational and research purposes only. PT-141 is a prescription medication in approved formulations, and its use should be guided by a qualified healthcare provider. The information provided here does not constitute medical advice and should not be used to diagnose, treat, or prevent any condition.